Aiplexity Investor Picks

Mar 24, 2026 Morning, N/A

02:00 PM UTC

Decision: After a comprehensive screening of the S&P 500, Dow 30, and recent market catalysts on March 24, 2026, the final selection is N/A [selecttopcandidate_v2].
Rationale: No single stock met the strict "Momentum/News Clause," which requires a fresh 12-48 hour catalyst, abnormally high relative volume (>1.1), and a non-overextended technical profile (<1.5 ATR from the 20-day SMA).
Candidates Evaluated: Key candidates like GSK (FDA approval), GME (Earnings), and AMZN (Cloud catalysts) failed to generate the required volume spike [selecttopcandidate_v2].
Risk Avoidance: The only candidate with significant momentum, NCEW, was disqualified for being severely overextended (2.35x ATR above its 20-day SMA), posing an unfavorable risk/reward for a 7-day horizon .
Market Context: While regional economic data (Richmond Fed) showed slight improvement in services, the broader market lacks a clear, high-conviction breakout leader today [tradingeconomics].

N/A: No specific company is recommended today. The focus remains on the broader market's failure to produce a high-probability breakout candidate that satisfies all risk management gates.

Sector Performance: A review of the Energy, Technology, and Healthcare sectors showed isolated news (e.g., GSK in Healthcare, NCEW in Energy) but no coordinated sector-wide momentum [market_screening].
Competitive Landscape: In the absence of a clear leader, the competitive landscape is currently characterized by "wait-and-see" behavior from institutional participants, as evidenced by the lack of relative volume across major catalyst-driven stocks [selecttopcandidate_v2].

Market Health: The screening process explicitly excluded stocks with high bankruptcy risk or distressed financials.
Candidate Quality: While companies like GSK and AMZN possess sound financials, their lack of immediate price/volume confirmation makes them unsuitable for a 7-day momentum strategy.
Risk of Overextension: The rejection of NCEW highlights the commitment to avoiding stocks where the "easy money" has already been made, protecting capital from potential mean-reversion pullbacks .

Patience as a Strategy: In a momentum-based framework, the most expensive mistake is "forcing" a trade when no high-conviction setup exists. For a 7-day horizon, the goal is to capture the "meat" of a fresh breakout.
Strict Filtering: By adhering to the 12-48 hour catalyst window and the 1.5 ATR overextension limit, we ensure that any recommendation has a mathematically sound risk/reward profile.
Conclusion: Because no stock currently offers both a fresh catalyst and a non-overextended entry with high volume, the highest-conviction move is to remain in N/A (cash/neutral) [selecttopcandidate_v2].

Overextension Risk: Entering stocks like NCEW at current levels (2.35x ATR above SMA20) carries a high probability of a "buy the news, sell the fact" reversal .
Volume Risk: Stocks with catalysts but low relative volume (GSK, GME) lack the institutional "gas" needed to sustain a move over the next 7 days [selecttopcandidate_v2].
Macro Risk: While Richmond Fed data was slightly positive, the "flat" manufacturing reading (0) suggests that industrial and cyclical stocks may face headwinds if growth remains tepid [tradingeconomics].

Final Pick: Symbol: N/A.
Plan: No position is recommended today. The strategy is to monitor for the next fresh catalyst that is accompanied by a relative volume spike (>1.1) and provides a low-risk entry point (within 1.5 ATR of the 20-day SMA).
Stop-Loss: Not applicable for a "no pick" scenario.